Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accumulated Expenses (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Accumulated Expenses data on record, last reported at $11.4 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 33.13% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, up 33.13%, while the annual FY2025 figure was $11.4 million, 33.13% up from the prior year.
  • Accumulated Expenses reached $11.4 million in Q4 2025 per FHTX's latest filing, up from $9.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.4 million in Q4 2025 and bottomed at $5.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $8.4 million, with a median of $8.6 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 57.14% in 2022, then dropped 29.06% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $9.6 million in 2021, then rose by 15.05% to $11.0 million in 2022, then dropped by 17.21% to $9.1 million in 2023, then decreased by 6.34% to $8.5 million in 2024, then surged by 33.13% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $11.4 million in Q4 2025, $9.8 million in Q3 2025, and $8.6 million in Q2 2025.